Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/94955
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia
Author: Bartley, P.
Latham, S.
Budgen, B.
Ross, D.
Hughes, E.
Branford, S.
White, D.
Hughes, T.
Morley, A.
Citation: The Journal of Molecular Diagnostics, 2015; 17(2):185-192
Publisher: Elsevier
Issue Date: 2015
ISSN: 1525-1578
1943-7811
Statement of
Responsibility: 
Paul A. Bartley, Susan Latham, Bradley Budgen, David M. Ross, Elizabeth Hughes, Susan Branford, Deborah White, Timothy P. Hughes, Alexander A. Morley
Abstract: The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic myeloid leukemia and has been used in research studies. We developed a DNA real-time quantitative PCR (qPCR) method for quantification of BCR-ABL1 sequences, which is also potentially suitable for routine use. The BCR-ABL1 breakpoint was sequenced after isolation by nested short-range PCR of DNA from blood, marrow, and cells on slides, obtained either at diagnosis or during treatment, or from artificial mixtures. PCR primers were chosen from a library of presynthesized and pretested BCR (n = 19) and ABL1 (n = 568) primers. BCR-ABL1 sequences were quantified relative to BCR sequences in 521 assays on 266 samples from 92 patients. For minimal residual disease detectable by DNA qPCR and RT-qPCR, DNA qPCR gave similar minimal residual disease results as RT-qPCR but had better precision at low minimal residual disease levels. The limit of detection of DNA qPCR depended on the amount of DNA assayed, being 10(-5.8) when 5 μg was assayed and 10(-7.0) when 80 μg was assayed. DNA qPCR may be useful and practical for monitoring the increasing number of patients with minimal residual disease around or below the limit of detection of RT-qPCR as the assay itself is simple and the up-front costs will be amortized if sequential assays are performed.
Keywords: Humans; Neoplasm, Residual; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Real-Time Polymerase Chain Reaction
Rights: © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
RMID: 0030026822
DOI: 10.1016/j.jmoldx.2014.10.002
Appears in Collections:Pathology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.